Your browser doesn't support javascript.
loading
Allopurinol use leading to xanthine nephrolithiasis in pediatric tumor lysis syndrome: a case series.
Goswami, Shrea; Hanson, Amy E; Rajadhyaksha, Evan; Dangle, Pankaj P; Schwaderer, Andrew L.
Afiliação
  • Goswami S; Indiana University Department of Pediatrics, Division of Nephrology, Riley Children's Hospital, 705 Riley Drive, Indianapolis, IN, 46202, USA.
  • Hanson AE; Indiana University Department of Pediatrics, Division of Critical Care, Indianapolis, IN, USA.
  • Rajadhyaksha E; Indiana University Department of Pediatrics, Division of Nephrology, Riley Children's Hospital, 705 Riley Drive, Indianapolis, IN, 46202, USA.
  • Dangle PP; Indiana University Department of Urology, Division of Pediatric Urology, Indianapolis, IN, USA.
  • Schwaderer AL; Indiana University Department of Pediatrics, Division of Nephrology, Riley Children's Hospital, 705 Riley Drive, Indianapolis, IN, 46202, USA. schwadea@iu.edu.
Pediatr Nephrol ; 2024 Jun 06.
Article em En | MEDLINE | ID: mdl-38842722
ABSTRACT
Tumor lysis syndrome (TLS) is a life-threatening metabolic disorder caused by massive tumor lysis. Allopurinol, a xanthine oxidase inhibitor, is initiated during chemotherapy to prevent hyperuricemia and subsequent acute kidney injury (AKI). We report two cases of xanthine nephrolithiasis during TLS in newly diagnosed hematologic malignancy patients receiving prophylactic allopurinol. Allopurinol use likely promoted xanthine crystallization, stone formation, and AKI.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article